Oncology Corporate Profile
Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential cancer treatment. Genmab's pipeline of fully human antibodies currently consists of 7 products in clinical development as well as numerous pre-clinical programs and other disease targets under exploration.
|Arzerra™||ofatumumab||ARZERRA (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated:|
- in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
- for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.
- for the treatment of patients with CLL refractory to fludarabine and
|Brand / Product||Class||Area of Study||Phase||Partnership|
|zalutumumab (+ radiotherapy) / HuMax-EGFr||anti-EGFR monoclonal antibody (humanized)||1st line metastatic Head & Neck cancer||III|
|Arzerra? / ofatumumab||anti-CD20 monoclonal antibody (humanized)||2nd line follicular Non-Hodgkin's Lymphoma (f-NHL)||III||GlaxoSmithKline|
|R1507||insulin-like growth factor-1 receptor (IGF-1R) inhibitor (monoclonal antibody)||Breast cancer||II||Genentech / Roche|
|R1507 (+ erlotinib)||insulin-like growth factor-1 receptor (IGF-1R) inhibitor (monoclonal antibody)||locally advanced Head & Neck cancer (squamous)||II||Genentech / Roche|
|daratumumab||CD38 monoclonal antibody||Multiple Myeloma||II||Janssen|
|R1507||insulin-like growth factor-1 receptor (IGF-1R) inhibitor (monoclonal antibody)||Non Small Cell Lung Cancer (NSCLC)||II||Genentech / Roche|
|R1507||insulin-like growth factor-1 receptor (IGF-1R) inhibitor (monoclonal antibody)||Sarcoma||II||Genentech / Roche|
|Arzerra? / ofatumumab (+ CHOP)||anti-CD20 monoclonal antibody (humanized)||1st line metastatic Non-Hodgkin?s lymphoma (NHL)||II||GlaxoSmithKline|
|Arzerra? / ofatumumab||anti-CD20 monoclonal antibody (humanized)||Diffuse large B-cell Lymphoma (DLBCL)||II||GlaxoSmithKline|
|Arzerra? / ofatumumab (+ chemotherapy)||anti-CD20 monoclonal antibody (humanized)||Diffuse large B-cell Lymphoma (DLBCL)||II||GlaxoSmithKline|
|zalutumumab (+ chemo-radiation) / HuMax-EGFr||anti-EGFR monoclonal antibody (humanized)||1st line metastatic Head & Neck cancer||I|
|zalutumumab (+ radiotherapy) / HuMax-EGFr||anti-EGFR monoclonal antibody (humanized)||Head & Neck cancer||I|
|HuMax-CD38Ž||anti-CD38 monoclonal antibody (humanized)||Multiple Myeloma||I|
|R1507||insulin-like growth factor-1 receptor (IGF-1R) inhibitor (monoclonal antibody)||Various cancer types||I||Genentech / Roche|
|R1507||insulin-like growth factor-1 receptor (IGF-1R) inhibitor (monoclonal antibody)||Various cancer types (pediatric)||I||Genentech / Roche|
|HuMax-CD32bŽ||anti-CD32 monoclonal antibody (humanized)||Various cancer types||Preclinical|
|HuMax-TFŽ||anti-tissue factor monoclonal antibody (humanized)||Various cancer types||Preclinical|
View additional information on product candidates here »
6/7/2016 02:02 pm
(OBI Pharma) June 5, 2016 - Results from phase II/III clinical trials show improvement in subset of patients who developed an immune response to vaccination.
5/5/2016 11:03 am
(Bloomberg) May 5, 2016 - Amgen Inc. is considering a bid for Medivation Inc., joining a group of suitors circling the cancer therapy company, according to people with knowledge of the matter.
5/4/2016 01:00 pm
(European Pharmaceutical Review) May 4, 2016 - The US Food and Drug Administration (FDA) has granted Priority Review to Lilly’s biologics license application (BLA) for olaratumab, in combination with doxorubicin, for the potential treatment of people with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery.
1/19/2016 02:02 pm
(Genmab A/S) Jan 19, 2016 - Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for the use of Arzerra® (ofatumumab) for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL).
8/17/2015 11:04 am
(NBC Nightly News) Aug 17, 2015 - Former President Jimmy Carter's cancer diagnosis, at age 90, is spotlighting how doctors treat cancer in the elderly.
8/14/2015 11:03 am
(Penn Medicine) Aug 13, 2015 - Insurance claims data hint at higher infection risk for Lucentis, a more expensive drug.
7/9/2015 11:44 am
(Reuters) July 8, 2015 - Novartis submitted an application to the European Medicines Agency (EMA) for the use of ofatumumab, branded as Arzerra, as maintenance therapy for patients with relapsed chronic lymphocytic leukemia, its co-developer Genmab said.
6/16/2015 11:04 am
(MedPage Today/The Gupta Guide) June 15, 2015 - Patients with relapsed myeloma lived twice as long without progression when treated with carfilzomib (Kyprolis) versus bortezomib (Velcade), a large randomized trial showed.
6/12/2015 11:00 am
(Morningstar) June 12, 2015 - Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced updated results of its pivotal phase III FIRST (MM-020/IFM 07-01) trial, comparing continuous REVLIMID® (lenalidomide) plus low-dose dexamethasone (continuous Rd) to a fixed duration of 18 cycles of Rd (72 weeks) (Rd18) or 12 cycles of melphalan, prednisone and thalidomide (72 weeks) (MPT) for the treatment of transplant ineligible patients with newly diagnosed multiple myeloma.
6/9/2015 12:00 pm
(Medscape Oncology) June 8, 2015 - A panel of community oncologists works on solutions to the most pressing issues facing their practices, including payment reform, alternative payment models, and pathways, as reported from ASCO 2015.
5/28/2015 12:02 pm
(IHME) May 28, 2015 - The number of incident cases of the cancers most common in men and women has jumped since 1990, while lung cancer is the leading cause of cancer death in the US.
4/7/2015 12:05 pm
(FDA.gov) Apr 6, 2015 - The U.S. Food and Drug Administration today approved the Gastric Emptying Breath Test (GEBT), a new non-invasive test to aid in the diagnosis of delayed gastric emptying, known as gastroparesis.
3/16/2015 11:01 am
(Heartwire from Medscape) Mar 15, 2015 - Although not exactly sure of the underlying mechanism or whether other factors are at play, researchers from Denmark note that patients who survive an MI may be at significant risk for overall and specific types of cancer.
2/27/2015 11:05 am
(EMA) Feb 27, 2015 - The European Medicines Agency (EMA) has recommended granting a conditional marketing authorisation for Zykadia (ceritinib).
2/27/2015 11:05 am
(Doctors Lounge/HealthDay News) Feb 26, 2015 - For patients with chronic lymphocytic leukemia, the Bruton tyrosine kinase inhibitor ibrutinib is effective, and prognosis is poor after discontinuation, according to a study published online Feb. 26 in JAMA Oncology.
2/4/2015 11:03 am
(Doctors Lounge/HealthDay News) Feb 4, 2015 - Fewer than half of Americans are aware that some major lifestyle factors can affect their cancer risk, a new survey suggests.
1/27/2015 11:04 am
(University of Maryland Medical Center) Jan 27, 2015 - Targeted biopsy using new fusion technology that combines magnetic resonance imaging (MRI) with ultrasound is more effective than standard biopsy in detecting high-risk prostate cancer, according to a large-scale study published today in JAMA.
1/27/2015 11:04 am
(Medscape Medical News) Jan 27, 2015 - The erectile dysfunction (ED) drugs often used after radical prostatectomy might increase the rate of the cancer's biochemical recurrence.
11/20/2014 05:01 am
(Reuters) Nov 20, 2014 - Sanofi and its U.S. partner Regeneron said on Thursday the U.S. Food and Drug Administration had designated their dupilumab drug as "breakthrough therapy" in the treatment of atopic dermatitis, a chronic form of eczema, granting the product a fast-track development and review process.
11/7/2014 06:01 am
(Baylor College of Medicine) Nov 7, 2014 - Researchers from Baylor College of Medicine have identified a network of proteins that triggers triple negative breast cancer – one of the most aggressive and difficult-to-treat forms of the disease.
10/30/2014 06:05 am
(Buffalo Business First) Oct 29, 2014 - The Leukemia & Lymphoma Society (LLS) is awarding $15.6 million in academic grants to 26 scientists who have proposed innovative laboratory research that shows promise in leading to new treatments for blood cancer patients.
10/29/2014 07:00 am
(Bloomberg) Oct 29, 2014 - Sanofi fired Chief Executive Officer Chris Viehbacher, ending a six-year tenure in which he caused tension with board members and French politicians by shifting the drugmaker’s focus to the U.S. and overhauling its struggling research operation.
10/15/2014 06:04 am
(Cincinnati Children's) Oct 14, 2014 - Doctors at Cincinnati Children’s Hospital Medical Center have developed a new technique for treating the eye cancer retinoblastoma to improve the odds for preventing eye loss, blindness or death in children with advanced forms of the disease.
8/5/2014 01:05 am
(Healio) Aug 5, 2014 - Results from an Independent Data Monitoring Committee interim analysis have found that ofatumumab met the primary endpoint of improving PFS among patients with relapsed chronic lymphocytic leukemia, manufacturers GlaxoSmithKline and Genmab reported.
7/21/2014 06:03 am
(Tyler Morning Telegraph [Tyler, Tex.]) July 20, 2014 - Cancer survivor Randy Childress joked that the disease was a great weight loss program when he was sick in the late ’90s, but 20 years of medical advances have continually improved the quality of life for survivors of the disease.
7/8/2014 06:05 am
(Reuters) July 8, 2014 - A uterine surgical technique that has been linked with the spread of a rare type of cancer poses a serious concern to regulators that will be addressed this week by an advisory committee to the U.S. Food and Drug Administration.